Latest Stories for AstraZeneca Promoted Stories,2015-03-22:/organization/675002015-03-22T13:28:10-07:00<![CDATA[PEGASUS-TIMI 54 Study Shows That Long-Term Treatment with BRILINTA Reduced Thrombotic Cardiovascular Events in Patients with a History of Heart Attack]]>,2015-03-14:3662362015-03-14T08:24:02-07:00logo

Data from 21,000 patient study presented at American College of Cardiology 64th Annual Scientific Session and simultaneously published in New England Journal of Medicine ]]>
<![CDATA[AstraZeneca, MD Anderson Enter Collaboration to Help Improve Patient Outcomes in Ovarian/ Gynecologic Cancers]]>,2015-01-29:3411622015-01-29T09:44:02-08:00logo

<![CDATA[PEGASUS-TIMI 54 Study of BRILINTA® Meets Primary Endpoint in Both 60mg and 90mg Doses]]>,2015-01-14:3532502015-01-14T04:01:24-08:00logo

BRILINTA 60mg and 90mg demonstrate statistically significant reduction in major cardiovascular thrombotic events in patients with a history of heart attack ]]>
<![CDATA[AstraZeneca Announces Plans to Expand its Frederick, Maryland Biologics Manufacturing Center]]>,2014-11-21:3152962014-11-21T08:08:02-08:00logo

$200+ Million Investment to Support Company’s Maturing Biologics Pipeline ]]>
<![CDATA[AstraZeneca Presents Data from Phase III Studies of Lesinurad in Combination with Allopurinol in Gout Patients at American College of Rheumatology 2014 Annual Meeting]]>,2014-11-16:3329962014-11-16T06:00:02-08:00logo

<![CDATA[AstraZeneca Announces Initiation of Development Program for BRILINTA (ticagrelor) Reversal Agent]]>,2014-11-13:3144792014-11-13T04:00:40-08:00logo

Updates on BRILINTA (ticagrelor) tablets development program and data from cardiovascular portfolio to be presented at American Heart Association (AHA) Scientific Sessions 2014 ]]>
<![CDATA[U.S. FDA Approves Once-Daily XIGDUO™ XR Tablets for Adults with Type 2 Diabetes]]>,2014-10-30:3173462014-10-30T04:02:15-07:00logo

First U.S. approval for once-daily tablet combining SGLT2 inhibitor and metformin HCl extended-release ]]>
<![CDATA[AstraZeneca Launches Fit2Me™, a Free Customized Diet and Lifestyle Support Program for People with Type 2 Diabetes]]>,2014-10-15:3101492014-10-15T04:30:14-07:00logo

<![CDATA[BRILINTA Preferred Over Clopidogrel in 2014 AHA/ACC Guideline for the Management of Non–ST-Elevation Acute Coronary Syndromes]]>,2014-10-06:3068242014-10-06T04:30:14-07:00logo

AHA/ACC Gives Class IIa Recommendation for Use of BRILINTA® (ticagrelor) Tablets Over Clopidogrel in NSTE-ACS Patients with Early Invasive or Ischemia-guided Strategy or Receiving a Coronary Stent ]]>
<![CDATA[FDA Approves MOVANTIK™ (naloxegol) Tablets C-II for the Treatment of Opioid-Induced Constipation in Adult Patients with Chronic Non-Cancer Pain]]>,2014-09-16:3008792014-09-16T10:58:02-07:00logo

<![CDATA[BYDUREON® Pen, a Treatment Option for Adults with Type 2 Diabetes, Now Available in Pharmacies]]>,2014-09-08:2974662014-09-08T04:00:52-07:00logo

<![CDATA[US Department of Justice Closes Investigation into PLATO Clinical Trial for BRILINTA]]>,2014-08-19:2922922014-08-19T04:00:49-07:00logo

<![CDATA[CDC Advisory Committee Recommends Preferential Use of Live Attenuated Influenza Vaccine (LAIV) for Eligible Children 2 to 8 Years of Age]]>,2014-06-26:2771672014-06-26T06:21:05-07:00logo

<![CDATA[New Study Reveals Significant Burden of RSV Disease Among U.S. Preterm Infants Born at 32-35 Weeks]]>,2014-06-03:2695602014-06-03T07:30:26-07:00logo

<![CDATA[FDA Approves EPANOVA For the Treatment of Adults with Severe Hypertriglyceridemia]]>,2014-05-06:2596822014-05-06T06:11:15-07:00logo